Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia

Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex

(2015) Anand Balasubramani et al.   Nature Communications

Erratum: Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

(2015) M M Patnaik et al.   Blood Cancer Journal

Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update

(2015) Kristen B. McCullough et al.   Current Hematologic Malignancy Reports

Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study

(2014) Emnet A. Wassie et al.   AMERICAN JOURNAL OF HEMATOLOGY

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

(2014) R. Bejar et al.   BLOOD

Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review

(2014) Mrinal M. Patnaik et al.   BRITISH JOURNAL OF HAEMATOLOGY

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients

(2014) M M Patnaik et al.   LEUKEMIA

Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia

(2013) O. Abdel-Wahab et al.   BLOOD

Clonal architecture of chronic myelomonocytic leukemias

(2013) R. Itzykson et al.   BLOOD

Clinical and biological implications of driver mutations in myelodysplastic syndromes

(2013) E. Papaemmanuil et al.   BLOOD

Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

(2013) Raphaël Itzykson et al.   JOURNAL OF CLINICAL ONCOLOGY

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML

(2013) R R Laborde et al.   LEUKEMIA

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes

(2013) M M Patnaik et al.   LEUKEMIA

SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)

(2012) M. Meggendorfer et al.   BLOOD

ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression

(2012) Omar Abdel-Wahab et al.   CANCER CELL

Effects ofTET2mutations on DNA methylation in chronic myelomonocytic leukemia

(2012) Jumpei Yamazaki et al.   Epigenetics

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms

(2011) O Abdel-Wahab et al.   LEUKEMIA

Cytogenetic risk stratification in chronic myelomonocytic leukemia

(2010) E. Such et al.   HAEMATOLOGICA

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1

(2010) Alexander Kohlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Mutations of polycomb-associated geneASXL1in myelodysplastic syndromes and chronic myelomonocytic leukaemia

(2009) Véronique Gelsi-Boyer et al.   BRITISH JOURNAL OF HAEMATOLOGY

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

(2009) O. Kosmider et al.   HAEMATOLOGICA

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML

(2009) A Tefferi et al.   LEUKEMIA